Who are the competitors of Onivyde?
Onivyde (irinotecan hydrochloride injection liposome) faces competition from several chemotherapy agents used to treat pancreatic cancer. These include gemcitabine and nab-paclitaxel, which are often used in combination [1]. Other drugs that may be used in treatment regimens for pancreatic cancer, and therefore represent competitive options, include fluoropyrimidines like capecitabine and 5-fluorouracil, as well as oxaliplatin [2][3].
How does Onivyde work compared to other pancreatic cancer treatments?
Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor. This delivery system is designed to prolong the circulation of irinotecan and deliver it to tumors [4]. In contrast, gemcitabine is a nucleoside analog that inhibits DNA synthesis and repair, while nab-paclitaxel is an albumin-bound paclitaxel that targets cancer cells [1][5]. The choice of treatment often depends on the stage of the cancer and whether it is a first-line or later-line therapy [6].
When does Onivyde's patent protection expire?
The patent landscape for Onivyde involves multiple patents. For example, U.S. Patent No. 8,409,621, which covers methods of treating pancreatic cancer with Onivyde, was challenged [7]. Information on the specific expiry dates of all relevant patents and any patent litigation can be found on DrugPatentWatch.com [7].
What are the risks and side effects associated with Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [4]. Serious side effects can include severe diarrhea, neutropenia, and hypersensitivity reactions [4]. These side effects are managed through dose adjustments and supportive care [4].
Can biosimilars or generics be developed for Onivyde?
The development of generic or biosimilar versions of Onivyde would depend on patent expiry and regulatory pathways. As a liposomal formulation, it presents unique manufacturing complexities for generic development [7].
What clinical trials have been conducted for Onivyde?
Onivyde has been studied in clinical trials, including the metastatic pancreatic cancer treatment of irinotecan and cisplatin versus gemcitabine and cisplatin [4]. Clinical data from these trials inform its use in specific patient populations and treatment settings [4][6].
What is the cost of Onivyde?
The cost of Onivyde can vary significantly based on insurance coverage, pharmacy, and dosage. However, it is generally considered an expensive cancer therapy [8].
What are the latest developments regarding Onivyde?
Ongoing research and clinical trials continue to explore the efficacy and optimal use of Onivyde, including in combination with other agents and in different lines of therapy [6].
Sources:
[1] https://www.cancer.gov/news-events/news-from-nci/2017/nab-paclitaxel-gemcitabine-pancreatic-cancer
[2] https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
[3] https://www.cancer.gov/types/pancreatic/patient/pancreatic-cancer-treatment-pdq
[4] https://www.fda.gov/drugs/drug-approvals/onivyde-irinotecan-hydrochloride-injection-liposome
[5] https://www.cancer.gov/publications/dictionaries/cancer-drug-terms/nab-paclitaxel
[6] https://ascopubs.org/doi/pdf/10.1200/JCO.2017.35.15_suppl.4063
[7] https://www.drugpatentwatch.com/p/irinotecan-hydrochloride-injection-liposome-us-patents
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780444/